Trust Signals
Reviewed by the FormBlends Medical Team. All claims are graded by evidence type. No affiliate relationships influence ratings. Sources are real, named, and linked where available. This page contains no sponsored content.Key Takeaways
- Sermorelin is a 29-amino-acid GHRH fragment with a plasma half-life of roughly 10 to 20 minutes; CJC-1295 with DAC extends this to roughly 6 to 8 days via albumin binding.
- The only published human RCT for CJC-1295 with DAC (Teichman et al. 2006, n=65) showed sustained IGF-1 elevation averaging roughly 28 to 43 percent above baseline depending on dose.
- Sermorelin has more historical human trial data including an FDA approval record, but its approval was withdrawn in 2008 for commercial reasons, not safety concerns.
- CJC-1295 without DAC (Modified GRF 1-29) is frequently mislabeled in compounding markets; buyers must confirm identity by mass spectrometry COA.
- Neither peptide has large phase 3 RCT evidence for body composition or anti-aging endpoints in healthy adults. Evidence for those outcomes is low to very low quality.
What Is the Difference Between CJC and Sermorelin?
Both are GHRH analogs that trigger the pituitary to release growth hormone, but they differ by half-life and pulse profile. Sermorelin produces short, physiologic GH pulses. CJC-1295 with DAC produces sustained GH and IGF-1 elevation lasting days. CJC-1295 without DAC behaves similarly to sermorelin. Neither is FDA approved for healthy adults.Table of Contents
- How do CJC and sermorelin work at the receptor level?
- Half-life and pharmacokinetics: the numbers that actually matter
- Evidence ledger: what the trials actually show
- What most pages get wrong about CJC vs sermorelin
- Head-to-head comparison table
- Formulation and stability: the chemistry behind storage rules
- Operational guide: how to read a COA and dose correctly
- Side effects and risks, graded by evidence
- FAQ
- Sources
How Do CJC and Sermorelin Work at the Receptor Level?
Both peptides bind the GHRH receptor (GHRH-R), a Gs-protein-coupled receptor expressed on somatotroph cells in the anterior pituitary. Binding activates adenylyl cyclase, raises intracellular cAMP, and triggers GH gene transcription and vesicular GH release. This mechanism is well-established and not in dispute.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Sermorelin is the first 29 amino acids of endogenous human GHRH (hGHRH 1-29 NH2). This 29-mer retains full GHRH-R binding activity because the receptor recognition domain resides within the first 29 residues. The remaining C-terminal amino acids of full-length GHRH (44 amino acids total) contribute to stability, not receptor binding.
CJC-1295 with DAC is a 30-mer analog with several amino acid substitutions relative to sermorelin, plus a maleimidopropionic acid (MPA) linker attached to a lysine at position 29. The MPA linker reacts covalently with cysteine-34 on circulating albumin. Because albumin has a half-life of roughly 19 days, this covalent bond dramatically extends the half-life of the active peptide from minutes to days. The receptor binding affinity of the core peptide is preserved.
CJC-1295 without DAC (often marketed as Modified GRF 1-29) carries amino acid substitutions designed to confer resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, modestly extending half-life relative to sermorelin without the albumin-binding mechanism. The precise substitution positions are described in the primary peptide chemistry literature; no single publicly verified source specifies every position uniformly across all published accounts, and position-level detail should be confirmed against a supplier COA and mass spectrometry data rather than taken from secondary sources.
What this mechanism does NOT prove: Prolonged GHRH receptor stimulation is not the same as physiologic GH secretion. Natural GH release is pulsatile, with troughs that appear necessary for receptor sensitivity. Whether sustained GH elevation from CJC-1295 with DAC produces better clinical outcomes than pulse-mimicking sermorelin in humans has not been tested in a powered comparative trial.
Half-Life and Pharmacokinetics: The Numbers That Actually Matter
| Compound | Plasma Half-Life | Dosing Frequency (typical) | GH Pulse Profile | Source |
|---|---|---|---|---|
| Sermorelin | 10 to 20 minutes | Daily (bedtime SQ) | Sharp pulse, mirrors physiology | Prakash and Goa, 1999 (Drugs) |
| CJC-1295 without DAC (Mod GRF 1-29) | Approximately 30 minutes | Daily, often with GHRP | Moderate pulse, DPP-IV resistant | Mechanistic inference; no dedicated human PK trial |
| CJC-1295 with DAC | Approximately 6 to 8 days | Once or twice weekly | Sustained plateau elevation | Teichman et al. 2006 (J Clin Endocrinol Metab) |
In the Teichman et al. 2006 trial (n=65 healthy adults, dose range 30 to 60 mcg/kg), mean GH concentrations remained elevated for more than 6 days after a single injection of CJC-1295 with DAC. IGF-1 increased 28 to 43 percent above baseline across dose groups and remained elevated for 9 to 11 days. This is the only robust human pharmacokinetic dataset for CJC-1295 with DAC.
Evidence Ledger: What the Trials Actually Show
| Claim | Best Evidence Type | Key Reference | Effect Direction | Confidence |
|---|---|---|---|---|
| Sermorelin raises GH in GH-deficient adults | Human RCTs, FDA review | Vittone et al. 1997; FDA approval record | Positive | High |
| CJC-1295 with DAC raises IGF-1 in healthy adults | Single human RCT (n=65) | Teichman et al. 2006 | Positive (28-43%) | Moderate |
| Sermorelin improves body composition in healthy aging adults | Small RCT | Vittone et al. 1997 (n=24) | Modest positive | Low |
| CJC-1295 improves body composition | No human RCT for this endpoint | None identified | Unknown | Very Low |
| Modified GRF 1-29 raises GH via GHRH-R | Mechanistic, animal, small human | Class mechanism; no dedicated trial | Presumed positive | Low |
| Combining GHRH analog with GHRP is synergistic | Human mechanistic studies | Bowers et al. 1990s literature | Positive (additive to synergistic) | Moderate (mechanism); Low (clinical outcomes) |
| CJC-1295 is safe in humans at tested doses | Single RCT, short follow-up | Teichman et al. 2006 | No serious adverse events reported | Low (limited follow-up) |
What Most Pages Get Wrong About CJC vs Sermorelin
1. The DAC confusion is rampant. The majority of wellness blogs treat "CJC-1295" as a single compound. It is not. CJC-1295 with DAC and CJC-1295 without DAC (Modified GRF 1-29) have different half-lives, different dosing schedules, and different risk profiles. Conflating them corrupts every comparison. When a compounding pharmacy prescribes "CJC-1295," you must confirm which variant is dispensed.
2. Half-life is not the same as efficacy. Longer half-life is a pharmacokinetic property, not a clinical outcome. The assumption that sustained IGF-1 elevation from CJC-1295 with DAC translates into superior fat loss, muscle gain, or recovery compared to sermorelin's pulse-based stimulation is mechanistically plausible but unproven in a head-to-head human trial.
3. Sermorelin's withdrawal is mischaracterized. Many pages imply sermorelin was pulled because it was replaced by something better or because it failed. Serono withdrew Geref in 2008 for commercial reasons. The compound itself remains manufacturable and is available through compounding pharmacies. Its safety and efficacy record in GH deficiency is intact.
4. Compounded peptide purity is not guaranteed. Analyses of commercially available research peptides have documented significant identity and purity problems in unregulated markets. Compounding pharmacies registered with state boards and following USP standards are a different tier than unregulated research chemical suppliers, but even compounding carries formulation variability. A COA with HPLC and MS data is the minimum meaningful quality signal.
Head-to-Head Comparison Table
| Factor | Sermorelin | CJC-1295 without DAC | CJC-1295 with DAC | Winner |
|---|---|---|---|---|
| Human trial depth | Multiple RCTs + FDA record | Minimal dedicated trials | One RCT (n=65) | Sermorelin |
| Pulse fidelity | Best (most physiologic) | Good | Poor (blunted plateau) | Sermorelin or Mod GRF 1-29 |
| Dosing convenience | Daily injection required | Daily injection required | Once or twice weekly | CJC-1295 with DAC |
| IGF-1 elevation (human data) | Documented in GHD | Presumed, no direct trial | 28-43% above baseline | CJC-1295 with DAC (by data, not necessarily outcome) |
| Body composition RCT evidence | Weak (small trial) | None | None | None win; all very low evidence |
| Regulatory status (US) | Compounded only (post-2008) | Research/compounded | Research/compounded | Sermorelin (cleaner history) |
| Identity/purity risk | Moderate | High (frequent mislabeling) | Moderate | Sermorelin (simpler molecule) |
| Cost (compounded, typical) | Lower | Moderate | Moderate to higher | Sermorelin |
| Comparison to exogenous HGH | Loses on IGF-1 magnitude | Loses on IGF-1 magnitude | Loses on IGF-1 magnitude | Exogenous HGH (if goal is maximal IGF-1) |
Honest concession: If the goal is maximum, documented IGF-1 elevation, recombinant HGH outperforms all GHRH analogs. GHRH analogs offer the theoretical advantage of preserving pituitary feedback regulation and may carry lower risk of receptor downregulation, but this advantage has not been demonstrated in a long-term comparative trial in humans.
Formulation and Stability: The Chemistry Behind Storage Rules
Both sermorelin and CJC-1295 are polypeptides vulnerable to two primary degradation pathways: hydrolysis and oxidation.
Hydrolysis of the peptide backbone occurs when water molecules attack amide bonds. Rate increases with temperature (roughly doubling per 10 degrees C, per Arrhenius kinetics) and at extremes of pH. This is why lyophilized (freeze-dried) powder is far more stable than reconstituted solution: removing water halts hydrolytic degradation almost entirely at room temperature.
Oxidation primarily targets methionine and tryptophan residues if present, and cysteine if free sulfhydryl groups are exposed. Sermorelin lacks methionine in its 29-mer sequence, which contributes to reasonable lyophilized stability. The MPA linker on CJC-1295 with DAC contains a maleimide group that, before albumin binding, can undergo hydrolysis at physiologic pH, which is one reason reconstituted CJC-1295 with DAC degrades faster than the lyophilized form.
Bacteriostatic water vs sterile water: Reconstitution with bacteriostatic water (0.9% benzyl alcohol) is used for multi-dose vials to prevent microbial growth. Benzyl alcohol can accelerate peptide oxidation over time in some formulations. For single-use or short-course peptides, sterile water minimizes this risk. Compounding pharmacy guidance typically specifies bacteriostatic water with a 28 to 30 day refrigerated use window.
Practical rule with the chemistry behind it: Store lyophilized vials at 2 to 8 degrees C or frozen. Reconstitute only what you need. Keep reconstituted solution refrigerated, out of light, and use within 30 days. Do not freeze reconstituted peptide; ice crystal formation during freeze-thaw cycles disrupts tertiary structure. Do not mix with acidic compounds (vitamin C solutions) as low pH accelerates hydrolysis of the peptide backbone.
Operational Guide: How to Read a COA and Dose Correctly
What a legitimate COA must show:
- HPLC purity greater than 98 percent (single peak, correct retention time)
- Mass spectrometry identity confirmation (molecular weight match within 1 Da)
- Endotoxin testing (LAL test, less than 1 EU/mg for injectable grade)
- Sterility testing for compounded injectable preparations
- Lot number and expiration date
Reconstitution math example (sermorelin 6 mg vial):
- Add 3 mL bacteriostatic water to the 6,000 mcg vial
- Concentration = 2,000 mcg/mL (2 mcg per microliter)
- For a 300 mcg dose, draw 0.15 mL (15 units on a U100 insulin syringe)
- Always inject using a U100 insulin syringe subcutaneously into abdomen or thigh
What a degraded product looks like: Lyophilized cake should be white to off-white, intact, not collapsed or discolored. Reconstituted solution should be clear and colorless. Yellow or brown coloration indicates oxidative degradation. Particulates or cloudiness indicate contamination or aggregation. Discard any vial showing these signs.
Label red flags for CJC specifically: If a product is simply labeled "CJC-1295" with no DAC or "no DAC" designation, contact the supplier for clarification before use. The two compounds require different dosing schedules. Dosing CJC-1295 with DAC on a daily schedule risks GH axis desensitization over time due to sustained non-pulsatile stimulation.
Side Effects and Risks, Graded by Evidence
| Side Effect | Evidence Type | Confidence | Notes |
|---|---|---|---|
| Injection site redness, pain | Human RCT (Teichman 2006) | Moderate | Most common adverse event in trial |
| Transient flushing or warmth post-injection | Human trial and clinical reports | Moderate | Class effect of GHRH stimulation |
| Water retention | Clinical observation, GH class effect | Low | More likely with sustained GH elevation |
| Elevated fasting glucose | Mechanism (GH is counter-regulatory); weak clinical signal | Low | Monitor in pre-diabetic patients |
| Antibody formation to sermorelin | FDA review data | Moderate | Rarely clinically significant; occurred in a minority of long-term users |
| IGF-1 overshoot, acromegaloid risk | Theoretical; no documented cases at standard doses | Very Low | Theoretical concern with CJC-1295 with DAC long-term |
| Pituitary receptor downregulation with chronic use | Animal data; human duration unknown | Low | More concern with CJC-1295 with DAC than pulsatile sermorelin |
FAQ
What is the main difference between CJC-1295 and sermorelin?
Sermorelin is a 29-amino-acid fragment of endogenous GHRH with a half-life of roughly 10 to 20 minutes. CJC-1295 with DAC is a modified 30-mer that binds albumin via a Drug Affinity Complex linker, extending half-life to roughly 6 to 8 days. CJC-1295 without DAC (also called Modified GRF 1-29) has a half-life closer to 30 minutes and behaves more like sermorelin.
Which has more human trial evidence, CJC-1295 or sermorelin?
Sermorelin has more human trial data, including FDA approval history (withdrawn in 2008 for commercial reasons, not safety). CJC-1295 with DAC has one published human pharmacokinetic RCT (Teichman et al. 2006, n=65) showing sustained GH and IGF-1 elevation. Neither has large phase 3 efficacy trials for body composition in healthy adults.
Can you combine CJC-1295 with a GHRP like ipamorelin?
Yes. GHRH analogs and GHRPs act on different receptors (GHRH-R and GHS-R1a respectively) and produce synergistic GH release. This combination is widely used in compounding pharmacy protocols. The evidence base for the combination specifically is limited to small clinical observations and mechanistic studies, not large RCTs.
Is CJC-1295 with DAC or without DAC better?
They serve different goals. CJC-1295 with DAC produces a prolonged, blunted GH curve suited to weekly or twice-weekly dosing. Without DAC (Modified GRF 1-29) produces a sharper, more physiologic pulse when injected, better mimicking natural GHRH. Neither is universally superior; pulse fidelity versus dosing convenience is the trade-off.
What dose of sermorelin is used clinically?
Historically, sermorelin was used at 0.2 to 0.3 mcg/kg subcutaneously at bedtime for GH deficiency testing and treatment. Compounding pharmacy protocols often use 200 to 500 mcg at bedtime, though these doses are not validated by large controlled trials in healthy adults.
Does sermorelin increase IGF-1 meaningfully in adults?
In adults with GH deficiency, sermorelin raised IGF-1 in controlled studies. In healthy aging adults, the effect is more modest and variable. The Vittone et al. 1997 trial in older adults showed IGF-1 increases with sermorelin treatment, but effect sizes were smaller than with direct GH.
What are the main side effects of CJC-1295 and sermorelin?
Both share a class-effect profile: injection site reactions, transient flushing or warmth, water retention, and potential for elevated blood glucose at higher GH levels. CJC-1295 with DAC carries a theoretical added concern of sustained GH elevation contributing to IGF-1 overshoot. Neither is approved for routine use in healthy adults.
Why was sermorelin withdrawn from the US market?
Sermorelin acetate (Geref) was withdrawn by Serono in 2008 for commercial and business reasons, not due to safety or efficacy concerns. It remains available through FDA-registered compounding pharmacies as a compounded preparation.
How should CJC-1295 or sermorelin be stored after reconstitution?
Both peptides should be stored refrigerated at 2 to 8 degrees C after reconstitution with bacteriostatic water. Sermorelin is generally considered stable for up to 30 days refrigerated once reconstituted, per compounding pharmacy guidelines. CJC-1295 lyophilized powder is stable at room temperature but once reconstituted should also be refrigerated and used within a similar window.
Is CJC-1295 detectable on drug tests?
WADA prohibits GHRH analogs including CJC-1295 and sermorelin under the Peptide Hormones class. Detection windows depend on the specific assay; WADA-accredited labs use LC-MS/MS methods. Athletes subject to testing should treat any GHRH analog as a prohibited substance.
What does a degraded or counterfeit GHRH peptide look like?
Degraded lyophilized peptide may appear discolored (yellow or brown instead of white) or may not dissolve cleanly. A legitimate COA from a compounding pharmacy or research supplier should include HPLC purity greater than 98 percent and mass spectrometry identity confirmation. Products lacking a COA or showing purity below 95 percent should not be used.
Sources
- Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Prakash A, Goa KL. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency." BioDrugs. 1999;12(2):139-157.
- Vittone J, et al. "Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men." Metabolism. 1997;46(1):89-96.
- Thorner MO, et al. "Physiological and clinical studies of GRF and GH." Recent Progress in Hormone Research. 1986;42:589-640.
- Bowers CY. "GH releasing peptides." Journal of Pediatric Endocrinology. 1993;6(1):21-31.
- World Anti-Doping Agency. "Prohibited List 2024: Section 2, Peptide Hormones, Growth Factors, Related Substances, and Mimetics." WADA, 2024. (wada-ama.org)
- FDA Drug Databases. "Sermorelin Acetate (Geref) NDA history." US Food and Drug Administration. (fda.gov)
- USP General Chapter 797. "Pharmaceutical Compounding: Sterile Preparations." United States Pharmacopeia.
Footer Disclaimers
Platform: This page is published by FormBlends for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before starting any peptide or hormone-related protocol.
Research Compound or Compounded Medication: CJC-1295 is not FDA approved for any indication. Sermorelin is available only as a compounded preparation in the US following withdrawal of the branded product. Compounded medications are not FDA approved and may vary in quality.
Results: Individual responses to GHRH analogs vary based on age, baseline GH status, body composition, and other factors. The clinical outcomes described in referenced studies may not reflect results achievable in all individuals.
Trademark: Geref is a trademark of Serono. FormBlends is not affiliated with any peptide manufacturer or compounding pharmacy. Product names used are for identification purposes only.